The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.

ABSTRACT:

Introduction

Breast cancer has traditionally been viewed as immunogenically 'cold,' but two immune checkpoint inhibitors have been approved in combination with chemotherapy for PD-L1 positive advanced triple-negative breast cancer (TNBC), and pembrolizumab was also recently approved for early stage TNBC. As the landscape is rapidly evolving, a comprehensive review of checkpoint inhibitors in breast cancer is needed to aid clinicians in selecting appropriate candidates for therapy, and to highlight ongoing promising studies in this area and topics in need of further investigation.

Area covered

This review summarizes the latest evidence from completed and ongoing trials of immune checkpoint inhibitors. Ongoing studies were identified using a search of ClinicalTrials.gov with t

SUBMITTER: Howard FM 

PROVIDER: S-EPMC8995399 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature